Study of Efficacy and Safety of LEE011 in Postmenopausal Women

To compare PFS between ribociclib in combination with fulvestrant to placebo in combination with fulvestrant among postmenopausal women with HR+, HER2-negative advanced breast cancer who received no or only one prior endocrine treatment for advanced disease

May 13, 2016